Study Findings. Among 21,653,835 (2021) and 19,978,911 (2022) patients, 312,708 prescriptions for varenicline were filled by 238,258 patients. After Chantix production was halted, a significant ...

More adults with exclusive daily e-cigarette use receiving 8-week varenicline quit than those receiving placebo, according to a research letter published in American Journal of Preventive Medicine ...

Varenicline is available in 0.5- and 1-mg tablets. The labeling information recommends adjusting the dosage from 0.5 mg once daily for days 1-3 to 0.5 mg twice daily for days 4-7, with a final ...

The U.S. drug regulator said on Friday it will temporarily allow manufacturers to distribute the anti-smoking drug varenicline with elevated levels of an impurity that may cause cancer, to ...

Pfizer is voluntarily recalling two lots of Chantix 0.5mg Tablets, two lots of Chantix 1 mg Tablets, and eight lots of a Chantix kit of 0.5mg/1 mg Tablets to the patient (consumer/user) level due ...

For every 100 people using varenicline, about 12 to 16 successfully quit, compared with around six in 100 who manage to quit without any aids. This means that varenicline can double—or even ...

The use of varenicline to stop smoking is associated with a 72 percent increased risk of a serious adverse cardiovascular event, according to a new study.

The researchers found that self-reported 7-day conventional cigarette smoking abstinence as confirmed by the exhaled carbon monoxide level on week 26 occurred in 40.4% in the EC group, 43.8% in ...

The varenicline group's cessation success rate being three times higher than that of the placebo group underscores the importance of pharmacological treatment in helping young people quit vaping.

The use of varenicline to stop smoking is associated with a 72 percent increased risk of a serious adverse cardiovascular event, states an article in CMAJ.

Compared with varenicline alone, combined nicotine replacement therapy and varenicline was superior for smoking cessation at 3 months (RR = 1.195; 95% CI, 1.048-1.363) and 6 months (RR = 1.376; 95 ...

PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray ...